Vulvovaginal Candidiasis

What is Vulvovaginal Candidiasis (VVC)?

VVC, commonly known as a vaginal yeast infection due to Candida, is the second most common cause of vaginitis.

References: 1. Rosati D, Bruno M, Jaeger M, Ten Oever J, Netea MG. Recurrent Vulvovaginal Candidiasis: An Immunological Perspective. Microorganisms. 2020;8(2):144. Published 2020 Jan 21. 2. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339-e347. 3. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961-1971. 4. Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal Candidiasis: A Current Understanding and Burning Questions. J Fungi (Basel). 2020;6(1):27. Published 2020 Feb 25. 5. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis. 2000;27(4):230-235. 6. Aballéa S, Guelfucci F, Wagner J, et al. Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes. 2013;11:169.

(Ibrexafungerp is not approved for the prevention of recurrent VVC.)

Ibrexafungerp for Prevention of Recurrent Vulvovaginal Candidiasis

Ibrexafungerp for Vulvovaginal Candidiasis

We believe ibrexafungerp has the potential to prevent recurrent vaginal yeast infections, also known as recurrent vulvovaginal candidiasis (VVC), across a broad range of patients for whom current treatment options are suboptimal. Despite yeast infections being so common, with millions of women suffering from them every year, recurrent VVC is still an under-appreciated, under-reported, and under-served women’s health condition.

Ibrexafungerp Key Attributes

“Many of the unresolved clinical issues in managing women with recurrent VVC would disappear if truly fungicidal drugs and regimens were available.”

- Dr. Jack D. Sobel
Current Infectious Disease Reports 2006,8:481–486

(Ibrexafungerp is not approved for the prevention of recurrent VVC.)

Clinical Development Plan

The CANDLE Phase 3 Study (ongoing) for the Prevention of Recurrent VVC

In March 2021, we completed enrollment in the CANDLE study ( identifier: NCT04029116).

development plan

development plan